Diabetes preceding Parkinson's disease onset. A case–control study

D'Amelio, Marco; Ragonese, Paolo; Callari, Graziella; Benedetto, Norma Di; Palmeri, Barbara; Terruso, Valeria; Salemi, Giuseppe; Famoso, Giorgia; Aridon, Paolo; Savettieri, Giovanni

doi:10.1016/j.parkreldis.2009.02.013

Cited by 66 publications

(58 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that these two diseases share many factors in terms of pathophysiology and clinical outcome and due to the similarity and the pathophysiological bridge between them, AD is often referred as “type 3 diabetes” [126,127]. There is also a link between diabetes and Parkinson’s disease [128]. Individuals with T2DM are at increased risk of developing PD [129,130].…”

Section: Discussionmentioning

confidence: 99%

Exposure to Environmental and Occupational Particulate Air Pollution as a Potential Contributor to Neurodegeneration and Diabetes: A Systematic Review of Epidemiological Research

Dimakakou

Johnston

Streftaris

et al. 2018

IJERPH

View full text Add to dashboard Cite

It has been hypothesised that environmental air pollution, especially airborne particles, is a risk factor for type 2 diabetes mellitus (T2DM) and neurodegenerative conditions. However, epidemiological evidence is inconsistent and has not been previously evaluated as part of a systematic review. Our objectives were to carry out a systematic review of the epidemiological evidence on the association between long-term exposure to ambient air pollution and T2DM and neurodegenerative diseases in adults and to identify if workplace exposures to particles are associated with an increased risk of T2DM and neurodegenerative diseases. Assessment of the quality of the evidence was carried out using the GRADE system, which considers the quality of the studies, consistency, directness, effect size, and publication bias. Available evidence indicates a consistent positive association between ambient air pollution and both T2DM and neurodegeneration risk, such as dementia and a general decline in cognition. However, corresponding evidence for workplace exposures are lacking. Further research is required to identify the link and mechanisms associated with particulate exposure and disease pathogenesis and to investigate the risks in occupational populations. Additional steps are needed to reduce air pollution levels and possibly also in the workplace environment to decrease the incidence of T2DM and cognitive decline.

show abstract

Section: Discussionmentioning

confidence: 99%

Exposure to Environmental and Occupational Particulate Air Pollution as a Potential Contributor to Neurodegeneration and Diabetes: A Systematic Review of Epidemiological Research

Dimakakou

Johnston

Streftaris

et al. 2018

IJERPH

View full text Add to dashboard Cite

show abstract

“…A lower incidence of diabetes in PD patients was found in the UK General Practice Research Database [23] . An Italian case-control study [24] based on self-reported information and reviews of medical documentations showed that 4.1% of PD patients and 9.8% controls reported a diagnosis of diabetes before PD diagnosis. Data were analyzed comparing smokers and non-smokers by BMI categories, alcohol and coffee consumption.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of Parkinson's Disease: A Population-Based Study in Primary Care in Italy

et al. 2016

View full text Add to dashboard Cite

Background: There are no studies on prevalence, incidence and comorbidities of Parkinson's disease (PD) in the Italian population. Methods: The database of 700 Italian general practitioners (population, 923,356) was investigated. All patients with International Classification of Diseases Ninth Revision - Clinical Modification (ICD-9-CM) diagnosis of PD during the period 2002-2012 were included. Parkinsonisms were excluded. Clinical conditions preceding PD were identified through ICD-9-CM codes. The Charlson Comorbidity Index was used. PD crude and standardized prevalence and annual incidence were calculated. Crude and adjusted hazard ratios were calculated for comorbidities. Results: A total of 2,204 patients (1,140 men, 1,064 women, age 22-95 years) were included. The crude prevalence of PD was 239/100,000. Prevalence increased exponentially with age. Standardized prevalence was 233 (95% CI 232-235). One hundred ninety-four patients were newly diagnosed, giving a crude incidence of 22/100,000 and a standardized incidence of 23.1/100,000 (95% CI 22.9-23.2). Incidence increased steadily until age 75-84 years and then decreased. Older age, cardiovascular and gastrointestinal disorders, diabetes, and restless-legs syndrome were associated with increased PD risk and smoking and hypersomnia with decreased PD risk. The Charlson Comorbidity Index was associated with PD risk with a documented gradient. Conclusions: Prevalence and incidence of PD in Italy are in line with studies with the highest case ascertainment. PD risk varies with the number and type of comorbidities.

show abstract

“…Notwithstanding the evidence supporting the association between PD and T2DM, there remains uncertainty given the studies that have found inverse associations (D'Amelio et al, 2009;Lu et al, 2014) or no association Savica et al, 2012).…”

Section: Epidemiological and Clinical Studies In Pd And T2dmmentioning

confidence: 99%

“…Case-control studies indicate that T2DM is associated with an increased risk of PD in some ethnic groups including Danish, Chinese and Taiwanese . Similarly, a positive association between PD and T2DM was indicated in large cohort studies and 62% of PD patients with dementia are insulin resistant Bosco et al, 2012).Notwithstanding the evidence supporting the association between PD and T2DM, there remains uncertainty given the studies that have found inverse associations (D'Amelio et al, 2009;Lu et al, 2014) or no association Savica et al, 2012).One possible factor that may explain the conflictive findings among epidemiological studies is that diagnosis of T2DM is sometimes based on self-report. Another important confounding factor is the impact of drugs used to treat patients with PD and T2DM.…”

mentioning

confidence: 99%

Splice Variant Biomarkers for Parkinson's Disease

Potashkin¹

2014

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. REPORT DATEMay PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) AND ADDRESS(ES) PERFORMING ORGANIZATION REPORT NUMBERRosalind Franklin U. Medicine & Science 3333 Green Bay Rd. North Chicago, IL 60064-3037 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTES ABSTRACTRecently we identified splice variants in whole blood than can distinguish early stage Parkinson's disease (PD) patients from healthy and neurodegenerative controls. The proposed studies will test the hypothesis that the biomarkers will be useful for identifying individuals at risk for PD and for identifying signaling pathways that are disrupted in PD. We are testing the expression of the biomarkers in RNA prepared from whole blood of hyposmic participants in the Parkinson's Associated Risk Study (PARS) (Technical Objective 1.0). In order to establish a model for testing the function of the biomarkers, we are determining whether their expression is altered in human olfactory neurosphere-derived (hONS) cells derived from idiopathic PD patients and healthy controls (Technical Objective 2.0). To determine the signaling pathways affected in PD and identify additional biomarkers, we are using network analysis (Technical Objective 3.0). During year 1, RNA and cDNA was prepared from PARS samples from Year 0 (baseline) and Year 2. Quantitative polymerase chain reactions were initiated for two of the biomarkers (APP, HNF4α). Expression of the biomarkers was tested in hONS. We also developed network approaches to reveal the common molecular pathways involved with PD and type 2 diabetes (T2DM). Using these networks, we identified APP, HNF4A and SOD2 mRNAs as blood biomarkers predictive of early stage PD. In addition, we determined that HNF4A mRNA may be a progression marker in blood for PD. SUBJECT TERMSParkinson's disease, biomarkers, neurodegeneration, network and pathway analysis 12-15Santiago 16-23Sei...

show abstract

Diabetes preceding Parkinson's disease onset. A case–control study

Cited by 66 publications

References 29 publications

Exposure to Environmental and Occupational Particulate Air Pollution as a Potential Contributor to Neurodegeneration and Diabetes: A Systematic Review of Epidemiological Research

Exposure to Environmental and Occupational Particulate Air Pollution as a Potential Contributor to Neurodegeneration and Diabetes: A Systematic Review of Epidemiological Research

Epidemiology of Parkinson's Disease: A Population-Based Study in Primary Care in Italy

Splice Variant Biomarkers for Parkinson's Disease

Contact Info

Product

Resources

About